

Dear Manufacturers,

I am writing on behalf of CHRISTUS Spohn Hospital Kleberg (CHSK; 340B ID: DSH450163 ) to inform manufacturers that CHSK recently underwent an audit by the Health Resources and Services Administration (HRSA) of CHSK's compliance with 340B Drug Pricing Program ("340B Program") requirements.

As background, CHSK qualified for the 340B Program as a disproportionate share hospital located at 1311 E. General Cavazos Blvd., Kingsville, TX 78363, and has participated in the 340B Program since September 9, 2005.

Through the audit process, CHSK was found to have non-compliance within its 340B program, and is responsible for repayment as a result of the following finding:

**CHSK dispensed 340B drugs to ineligible individuals as prohibited by 42 USC 256b(a)(5)(B)**

Covered entities are prohibited by 42 USC 256b(a)(5)(B) from reselling or otherwise transferring a 340B drug to a person who is not a patient of the covered entity. During the course of the audit, HRSA identified instances of retail prescriptions being filled at one of CHSK's contract pharmacies for patients who did not meet the patient definition guidelines.

CHSK has identified all affected manufacturers and has contacted each to notify them of these violations to begin a dialogue on a method for repayment to affected manufacturers. If manufacturers have not received notification from CHSK and believe repayment may be owed for the violations described in this letter, or if you have any questions or comments regarding the violations described in this letter please contact me:

Ms. Pamela L. Brower  
Chief Financial Officer  
CHRISTUS Spohn Hospital Kleberg  
1311 E. General Cavazos Blvd.  
Kingsville, TX 78363  
(361) 881-3432

Sincerely,

Pamela L. Brower  
Chief Financial Officer  
340B Responsible Authority for CHRISTUS Spohn Hospital Kleberg # DSH450163